. Author manuscript; available in PMC: 2018 Feb 1.

Published in final edited form as: Br J Haematol. 2017 May 9;178(4):561–570. doi: 10.1111/bjh.14731

Table 2.

Multivariate analysis for disease-free and overall survival

Covariate	Overall survival		Disease-free survival
Covariate	HR (95% CI)	P-Value	HR (95% CI)	P-Value
Treatment arm
SD-R	1	0.439	1	0.242
HD-R	0.81 (0.48 – 1.38)	0.439	0.74 (0.45 – 1.23)	0.242

Age in years
< 65	1	0.076	1	0.199
≥ 65	1.60 (0.95 – 2.68)	0.076	1.38 (0.84 – 2.25)	0.199

Disease status before translant
CR/CRu	1	0.032	1	0.024
PR/SD	1.79 (1.05 – 3.06)	0.032	1.79 (1.08 – 2.95)	0.024

No. of prior lines of treatmnet
≤ 2	1	0.002	1	0.016
> 2	2.30 (1.34 – 3.94)	0.002	1.89 (1.13 – 3.18)	0.016

Abbreviations: CR/CRu, complete remission/complete remission unconfirmed; HR, hazard ratio; HD-R, high-dose rituximab; No., number; PR/SD, partial response/stable disease; SD-R, standard-dose rituximab.